Kalaris Therapeutics raised $50M in an oversubscribed private placement to develop treatments for retinal diseases.
On December 17, 2025, Kalaris Therapeutics, Inc. disclosed that they have collaborated with a group of accredited investors to sell securities in a private placement deal, garnering around $50.0 million in total gross proceeds. This transaction precedes the company’s rigorous efforts in developing and marketing therapies for common retinal disorders.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments